Breast CancerPhase 1NCT03641755
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
A Phase 1 study testing Sapacitabine and Olaparib in people with Breast Cancer, run by Dana-Farber Cancer Institute at 2 sites in United States.
Trial summary
This research study is studying a combination of drugs as a possible treatment for breast cancer with a BRCA mutation. The interventions involved in this study are: Sapacitabine (CYC682) Olaparib (Lynparza™) Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Breast Cancer
- What is being tested?
- Sapacitabine and Olaparib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 2 sitesUnited States
- Study dates
- 1 Oct 2018to 22 Oct 2026
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically or cytologically confirmed breast cancer that is metastatic or unresectable.
- Documented germline mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function). Testing may be completed by any CLIA-certified laboratory.
- Patients with estrogen and/or progesterone receptor-positive disease must have received and progressed on at least one endocrine therapy (adjuvant or metastatic), or have disease that the treating physician believes to be inappropriate for endocrine therapy.
- Patients with HER2-positive disease must have received and progressed on two lines of HER2-directed therapy in the metastatic setting.
- Age ≥ 18 years
- ECOG performance status of 0-1 (please see Appendix A).
Show all 26Show fewer
- Participants enrolling to the phase I portion of the study must have evaluable or measurable disease; participants enrolling to the phase II portion of the study must have measurable disease per RECIST 1.1 criteria (please see Section 11).
- Adequate organ and bone marrow function as defined below:
- Hemoglobin ≥ 10 g/dL
- Absolute neutrophil count (ANC) ≥ 1.5 × 109/L
- Platelet count ≥ 100 × 109/L
- Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN)
- AST(SGOT) / ALT (SGPT) ≤ 2.5 × institutional ULN, OR
- AST(SGOT) / ALT (SGPT) ≤ 5 × institutional ULN if liver metastases are present
- Creatinine Clearance estimated (using the Cockcroft-Gault equation) of ≥ 51 mL/min
- Ability to understand and willingness to sign an informed consent document.
- Ability to swallow and retain oral study medication.
- Female participants must be postmenopausal or must have a negative serum pregnancy test performed during screening. Postmenopausal is defined as:
- Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments
- Luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the postmenopausal range for women under 50.
- Radiation-induced oophorectomy with last menses >1 year ago
- Chemotherapy-induced menopause with >1 year interval since last menses
- Status post surgical sterilization (bilateral oophorectomy or hysterectomy)
- The effects of sapacitabine and olaparib on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use two highly effective forms of contraception for the duration of study participation and 6 months after the last dose of sapacitabine and/or olaparib. Men must agree to use two highly effective forms of contraception for the duration of study participation and 3 months after the last dose of sapacitabine and/or olaparib. A list of acceptable methods is listed in Section 5.5.3.4.
- Participants must be willing and able to comply with the protocol for the duration of the study, including undergoing treatment and scheduled visits and examinations.
- Participants enrolling to the phase II portion of the trial must be willing to undergo a biopsy at baseline; if their disease is not accessible for biopsy they are still eligible to participate.
Who cannot join
- Any previous treatment with a PARP inhibitor, including but not limited to olaparib.
- Any previous treatment with sapacitabine.
- Patients who have had prior systemic chemotherapy, immune therapy, or investigational therapy within 3 weeks of study entry. Endocrine therapy must have been discontinued at least 7 days prior to Cycle 1 Day 1. Patients may receive bisphosphonates or denosumab during the study.
- Patients who have received prior radiotherapy within 1 week of study entry.
- Participants with active pneumonitis.
- Patients who have undergone major surgery or have ongoing persistent toxicities within 2 weeks prior to study entry. Patients must have recovered to baseline or ≤ Grade 1 from any effects of any major surgery prior to study entry with the exception of any grade of alopecia and persistent grade ≤ 2 peripheral neuropathy
Show all 25Show fewer
- For enrollment during phase II: patients who have received more than 3 prior lines of cytotoxic chemotherapy for metastatic disease. Prior treatments with hormonal therapy and non-hormonal targeted therapy are allowed and not counted as a prior line of cytotoxic chemotherapy. For the purposes of this protocol, the combination of an aromatase inhibitor and everolimus is not considered cytotoxic chemotherapy.
- Patients with a history of treated central nervous system (CNS) metastases are eligible, provided they meet all of the following criteria:
- Disease outside the CNS is present
- No clinical evidence of progression in the CNS since completion of CNS-directed therapy
- Minimum of 2 weeks between completion of radiotherapy and Cycle 1 Day 1
- Recovery from significant (≥ Grade 3) acute toxicity with no requirement for escalating doses of corticosteroid over the 7 days prior to treatment start.
- Participants requiring concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to study entry is 2 weeks.
- Participants requiring concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil). The required washout period prior to study entry is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
- Participants with a QTcF of >470 msec on screening ECG.
- Participants with a personal or family history of long QT syndrome.
- Pregnant women are excluded from this study because olaparib and sapacitabine are agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study agents, breastfeeding should be discontinued if the mother is treated with olaparib or sapacitabine and for one month after receiving the last dose.
- Participants with known active Hepatitis B, C, or known HIV positive status.
- Participants unable to swallow orally administered medication and participants with gastrointestinal disorders that are likely to interfere with absorption of the study medications in the opinion of the treating investigator (e.g. malabsorption syndrome or major stomach or bowel resections).
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to sapacitabine or olaparib.
- Patients with a history of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
- History of a previous allogeneic bone marrow transplant or double umbilical cord blood transplantation.
- Patients with a history of a second primary malignancy, with the following exceptions: adequately treated non-melanoma skin cancers, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS) of the breast, stage 1 grade 1 endometrial carcinoma, and any other solid tumor or lymphoma (without bone marrow involvement) diagnosed ≥ 5 years prior to study entry and treated with no evidence of disease recurrence; other exceptions may exist following agreement with the principal investigator who believes disease recurrence is unlikely.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Participants who are involved in the planning and/or conduct of the study (applies to both pharmaceutical company staff and/or staff at the study site).
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Dana Farber Cancer Institute
Boston, Massachusetts, 02215
Broad Institute of MIT
Cambridge, Massachusetts, 02142
About this study
Official title: A Phase Ib/II Study of Olaparib With Sapacitabine in BRCA Mutant Breast Cancer
This research study is studying a combination of drugs as a possible treatment for breast cancer with a BRCA mutation.
The interventions involved in this study are:
- Sapacitabine (CYC682)
- Olaparib (Lynparza™)
Read the detailed description
This is a Phase I/II clinical trial. A Phase I clinical trial tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies. "Investigational" means that the intervention is being studied. It also means that the FDA (the U.S. Food and Drug Administration) has not approved the combination of Olaparib and Sapacitabine as a treatment for any disease.
The FDA (the U.S. Food and Drug Administration) has approved Olaparib as a treatment for metastatic HER2 negative breast cancer with a BRCA mutation. Olaparib is an inhibitor of PARP (poly [adenosine diphosphate-ribose] polymerase), which means that it stops PARP from working. PARP is an enzyme (a type of protein) found in the cells of the body. In normal cells when DNA is damaged, PARP helps to repair the damage.
The FDA has not approved Sapacitabine for use in patients including people with this type of cancer. Sapacitabine and drugs of its class have been shown to have antitumor properties in many types of cancer, e.g., leukemia, lung, breast, ovarian, pancreatic and bladder cancer. Sapacitabine may help to stop the growth of some types of cancers.
In this research study, the investigators are evaluating the safety and effectiveness of Olaparib in combination with Sapacitabine in BRCA mutant breast cancer.
- Conditions
- Breast Cancer
- Being tested
- Sapacitabine, Olaparib
- Keywords
- Breast Cancer
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SapacitabineDrug
Also called CYC682
Sapacitabine may help to stop the growth of some types of cancers
OlaparibDrug
Also called Lynparza
Olaparib is an inhibitor of PARP (poly [adenosine diphosphate-ribose] polymerase), which means that it stops PARP from working
| Study group | Role | What they receive |
|---|---|---|
| Dose Level -1: Sapacitabine (100 mg) + Olaparib (300 mg) | Experimental | * Olaparib will be administered orally twice daily for each 28-day cycle
* Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle Receives: Drug: Sapacitabine; Drug: Olaparib |
| Dose Level 1: Sapacitabine (150 mg) + Olaparib (300 mg) | Experimental | * Olaparib will be administered orally twice daily for each 28-day cycle
* Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle Receives: Drug: Sapacitabine; Drug: Olaparib |
| Dose Level 2: Sapacitabine (200 mg) + Olaparib (300 mg) | Experimental | * Olaparib will be administered orally twice daily for each 28-day cycle
* Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle Receives: Drug: Sapacitabine; Drug: Olaparib |
| Dose Level 3: Sapacitabine (250 mg) + Olaparib (300 mg) | Experimental | * Olaparib will be administered orally twice daily for each 28-day cycle
* Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle Receives: Drug: Sapacitabine; Drug: Olaparib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Maximum Tolerated Dose (MTD)
The dose level immediately below the maximally-administered dose (MAD; defined as the dose level where at least two participants develop dose-limiting toxicity [DLT]) will be defined as the MTD. In the situation where none of the dose levels have ≥ 2 DLTs, the MTD will be the highest dose administered. The MTD will be established in a minimum of 6 participants.
Measured: Assessed from the time of the first patient registration to the time that the last patient comes off protocol therapy in the dose escalation phase, up to 41 months
Recommended Phase II dose (RPIID)
The highest dose level below the MAD at which ≤1 out of 6 patients develop DLT. The RPIID will be established in a minimum of 6 participants.
Measured: Assessed from the time of the first patient registration to the time that the last patient comes off protocol therapy, up to 41 months
Objective Response Rate
Defined as the percentage of patients achieving a complete response (disappearance of all target and non-target lesions; no new lesions) or partial response (at least 30% decrease in the sum of the diameters of target lesions; persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits ["non-CR/non-PD" in non-target lesions]; and no new lesions) based on RECIST 1.1
Measured: Assessed for each patient from the time of registration until 30 days after removal from protocol therapy or until death, whichever occurs first, up to 41 months
Secondary outcomes (2)
Progression-Free Survival
Defined as the time from registration to the earlier of progression by RECIST 1.1 or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation.
Measured: Assessed for each patient from the time of registration until 30 days after removal from protocol therapy or until death, whichever occurs first, up to 41 months
Dose Limiting Toxicity
Evaluated among participants enrolled to the phase I trial during the first cycle of therapy. DLTs are defined as toxicities that are considered at least possibly related to the study regimen and that fit one or more of the following criteria:
- Any death not clearly due to the underlying disease or extraneous causes
- Any non-hematologic toxicity ≥ Grade 3
- Any occurrence of Hy's Law (see protocol Appendix B)
- Febrile neutropenia ≥ Grade 3
- Grade 4 neutropenia or thrombocytopenia lasting >7 days
- Thrombocytopenia with bleeding ≥ Grade 3
- ≥ Grade 3 nausea, vomiting, diarrhea lasting > 72 hours with adequate antiemetic or other supportive care.
- ≥ Grade 3 fatigue lasting > 7 days
- ≥Grade 3 electrolyte abnormality that lasts > 72 hours with no clinical symptoms.
- ≥ Grade 3 electrolyte abnormality with clinical symptoms, regardless of duration.
Toxicities are defined according to NCI CTCAE, Version 5.0
Measured: Assessed for each patient from the start of protocol therapy to the end of the first cycle of therapy (28 days post start of therapy)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Aug 2018
- Study start1 Oct 2018
- Primary completion27 Apr 2022
- Study completion22 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Dana-Farber Cancer InstituteThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dana-Farber Cancer Institute
- Sponsor type
- University, hospital or other
- Collaborators
- AstraZeneca, Cyclacel Pharmaceuticals, Inc.
- Responsible party
- Principal investigator, Filipa Lynce, MD, Dana-Farber Cancer Institute
- Investigators
- Filipa Lynce, MD, Principal investigator, Dana-Farber Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03641755
- Sponsor's protocol ID
- 18-223
- Status last verified
- Jan 2026
- First submitted
- 20 Aug 2018
- Last updated
- 23 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase Ib/II Study of Olaparib With Sapacitabine in BRCA Mutant Breast Cancer
- ClinicalTrials.gov ID
- NCT03641755
- Acronym / sponsor ID
- 18-223
- Conditions
- Breast Cancer
- Keywords
- Breast Cancer
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 10 participants (actual)
- Lead sponsor
- Dana-Farber Cancer InstituteUniversity, hospital or other
- Collaborators
- AstraZeneca, Cyclacel Pharmaceuticals, Inc.
- Study start
- 1 Oct 2018 (actual)
- Primary completion
- 27 Apr 2022 (actual)
- Study completion
- 22 Oct 2026 (estimated)
- First posted
- 22 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This research study is studying a combination of drugs as a possible treatment for breast cancer with a BRCA mutation.
The interventions involved in this study are:
- Sapacitabine (CYC682)
- Olaparib (Lynparza™)
Detailed description
This is a Phase I/II clinical trial. A Phase I clinical trial tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies. "Investigational" means that the intervention is being studied. It also means that the FDA (the U.S. Food and Drug Administration) has not approved the combination of Olaparib and Sapacitabine as a treatment for any disease.
The FDA (the U.S. Food and Drug Administration) has approved Olaparib as a treatment for metastatic HER2 negative breast cancer with a BRCA mutation. Olaparib is an inhibitor of PARP (poly [adenosine diphosphate-ribose] polymerase), which means that it stops PARP from working. PARP is an enzyme (a type of protein) found in the cells of the body. In normal cells when DNA is damaged, PARP helps to repair the damage.
The FDA has not approved Sapacitabine for use in patients including people with this type of cancer. Sapacitabine and drugs of its class have been shown to have antitumor properties in many types of cancer, e.g., leukemia, lung, breast, ovarian, pancreatic and bladder cancer. Sapacitabine may help to stop the growth of some types of cancers.
In this research study, the investigators are evaluating the safety and effectiveness of Olaparib in combination with Sapacitabine in BRCA mutant breast cancer.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Dose Level -1: Sapacitabine (100 mg) + Olaparib (300 mg) | Experimental | Drug: Sapacitabine, Drug: Olaparib* Olaparib will be administered orally twice daily for each 28-day cycle * Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle |
| Dose Level 1: Sapacitabine (150 mg) + Olaparib (300 mg) | Experimental | Drug: Sapacitabine, Drug: Olaparib* Olaparib will be administered orally twice daily for each 28-day cycle * Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle |
| Dose Level 2: Sapacitabine (200 mg) + Olaparib (300 mg) | Experimental | Drug: Sapacitabine, Drug: Olaparib* Olaparib will be administered orally twice daily for each 28-day cycle * Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle |
| Dose Level 3: Sapacitabine (250 mg) + Olaparib (300 mg) | Experimental | Drug: Sapacitabine, Drug: Olaparib* Olaparib will be administered orally twice daily for each 28-day cycle * Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (26 listed)
- Histologically or cytologically confirmed breast cancer that is metastatic or unresectable.
- Documented germline mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function). Testing may be completed by any CLIA-certified laboratory.
- Patients with estrogen and/or progesterone receptor-positive disease must have received and progressed on at least one endocrine therapy (adjuvant or metastatic), or have disease that the treating physician believes to be inappropriate for endocrine therapy.
- Patients with HER2-positive disease must have received and progressed on two lines of HER2-directed therapy in the metastatic setting.
- Age ≥ 18 years
Key exclusion criteria (25 listed)
- Any previous treatment with a PARP inhibitor, including but not limited to olaparib.
- Any previous treatment with sapacitabine.
- Patients who have had prior systemic chemotherapy, immune therapy, or investigational therapy within 3 weeks of study entry. Endocrine therapy must have been discontinued at least 7 days prior to Cycle 1 Day 1. Patients may receive bisphosphonates or denosumab during the study.
- Patients who have received prior radiotherapy within 1 week of study entry.
- Participants with active pneumonitis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SapacitabineAlso: CYC682Sapacitabine may help to stop the growth of some types of cancers | Drug | Dose Level -1: Sapacitabine (100 mg) + Olaparib (300 mg), Dose Level 1: Sapacitabine (150 mg) + Olaparib (300 mg), Dose Level 2: Sapacitabine (200 mg) + Olaparib (300 mg), Dose Level 3: Sapacitabine (250 mg) + Olaparib (300 mg) |
| OlaparibAlso: LynparzaOlaparib is an inhibitor of PARP (poly [adenosine diphosphate-ribose] polymerase), which means that it stops PARP from working | Drug | Dose Level -1: Sapacitabine (100 mg) + Olaparib (300 mg), Dose Level 1: Sapacitabine (150 mg) + Olaparib (300 mg), Dose Level 2: Sapacitabine (200 mg) + Olaparib (300 mg), Dose Level 3: Sapacitabine (250 mg) + Olaparib (300 mg) |
Primary outcome
Maximum Tolerated Dose (MTD)
Time frame: Assessed from the time of the first patient registration to the time that the last patient comes off protocol therapy in the dose escalation phase, up to 41 months
The dose level immediately below the maximally-administered dose (MAD; defined as the dose level where at least two participants develop dose-limiting toxicity [DLT]) will be defined as the MTD. In the situation where none of the dose levels have ≥ 2 DLTs, the MTD will be the highest dose administered. The MTD will be established in a minimum of 6 participants.
Recommended Phase II dose (RPIID)
Time frame: Assessed from the time of the first patient registration to the time that the last patient comes off protocol therapy, up to 41 months
The highest dose level below the MAD at which ≤1 out of 6 patients develop DLT. The RPIID will be established in a minimum of 6 participants.
Objective Response Rate
Time frame: Assessed for each patient from the time of registration until 30 days after removal from protocol therapy or until death, whichever occurs first, up to 41 months
Defined as the percentage of patients achieving a complete response (disappearance of all target and non-target lesions; no new lesions) or partial response (at least 30% decrease in the sum of the diameters of target lesions; persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits ["non-CR/non-PD" in non-target lesions]; and no new lesions) based on RECIST 1.1
2 secondary outcomes
Progression-Free Survival
Time frame: Assessed for each patient from the time of registration until 30 days after removal from protocol therapy or until death, whichever occurs first, up to 41 months
Dose Limiting Toxicity
Time frame: Assessed for each patient from the start of protocol therapy to the end of the first cycle of therapy (28 days post start of therapy)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Filipa Lynce, MD principal investigator
Dana-Farber Cancer Institute
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Sapacitabine and Olaparib in people with Breast Cancer, run by Dana-Farber Cancer Institute at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 26 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 23 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Maximum Tolerated Dose (MTD) (time frame: Assessed from the time of the first patient registration to the time that the last patient comes off protocol therapy in the dose escalation phase, up to 41 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2026.